EGFR and non-small cell lung carcinoma: Scagliotti et al. (2017) carried out a phase III clinical trial comparing erlotinib (150 mg/day) plus tivantinib (360 mg twice/day) vs. erlotinib alone (150 mg/day) for EGFR-mutant NSCLC.